You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in


Carter, J Elliot MD; Laurini, Javier A. MD; Mizell, Kelly N. MD

Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e318170af5b
Brief Reports

In pediatric patients, Kluyvera spp. has emerged as a cause of disease ranging from soft tissue infections to sepsis with multiorgan failure. Successful treatment options include third-generation cephalosporins, tetracycline, aminoglycosides, and fluoroquinolones, but resistance to first- and second-generation cephalosporins persists. Clinicians should be aware of the spectrum of disease and increasing clinical importance associated with this emerging pathogen.

Author Information

From the Department of Pathology, University of South Alabama, Mobile, AL.

Accepted for publication February 26, 2008.

Address for correspondence: J. Elliot Carter, MD, Department of Pathology, University of South Alabama, 2451 Fillingim Street, Mobile, AL 36617. E-mail:

© 2008 Lippincott Williams & Wilkins, Inc.